EBS Emergent BioSolutions Inc. Stock Quote

EBS [NYSE]

Healthcare | Drug Manufacturers - Specialty & Generic | USA

Index	-	P/E	12.06	EPS (ttm)	5.63	Insider Own	2.70%	Shs Outstand	53.30M	Perf Week	-10.53%
Market Cap	3.49B	Forward P/E	12.68	EPS next Y	5.35	Insider Trans	-13.33%	Shs Float	45.20M	Perf Month	-23.13%
Income	305.10M	PEG	1.31	EPS next Q	1.15	Inst Own	84.10%	Short Float	5.75%	Perf Quarter	-36.15%
Sales	1.56B	P/S	2.24	EPS this Y	445.20%	Inst Trans	2.89%	Short Ratio	3.55	Perf Half Y	-31.82%
Book/sh	27.15	P/B	2.50	EPS next Y	-42.28%	ROA	11.90%	Target Price	113.86	Perf Year	1.06%
Cash/sh	12.09	P/C	5.61	EPS next 5Y	9.20%	ROE	24.50%	52W Range	64.04 - 137.61	Perf YTD	-24.25%
Dividend	-	P/FCF	8.83	EPS past 5Y	24.00%	ROI	14.30%	52W High	-50.68%	Beta	1.07
Dividend %	-	Quick Ratio	2.30	Sales past 5Y	26.00%	Gross Margin	67.40%	52W Low	5.98%	ATR	4.07
Employees	2200	Current Ratio	3.10	Sales Q/Q	61.80%	Oper. Margin	27.90%	RSI (14)	28.96	Volatility	5.27% 4.31%
Optionable	Yes	Debt/Eq	0.60	EPS Q/Q	283.00%	Profit Margin	19.60%	Rel Volume	2.24	Prev Close	77.64
Shortable	Yes	LT Debt/Eq	0.58	Earnings	Apr 29 AMC	Payout	0.00%	Avg Volume	732.63K	Price	67.87
Recom	2.00	SMA20	-19.34%	SMA50	-28.81%	SMA200	-31.68%	Volume	1,603,844	Change	-12.58%

Apr-07-21

Initiated

The Benchmark Company

Buy

$150

Feb-24-21

Upgrade

Chardan Capital Markets

Neutral → Buy

$112

Feb-19-21

Downgrade

Chardan Capital Markets

Buy → Neutral

$112

Jan-08-21

Downgrade

Wells Fargo

Overweight → Equal Weight

$110

Sep-14-20

Resumed

JP Morgan

Neutral

$103

Jul-31-20

Reiterated

Chardan Capital Markets

Buy

$86 → $112

Sep-12-19

Initiated

Guggenheim

Buy

Sep-04-19

Upgrade

Wells Fargo

Market Perform → Outperform

Nov-02-18

Upgrade

Goldman

Neutral → Buy

Aug-03-18

Reiterated

Chardan Capital Markets

Buy

$53 → $57

Jun-13-18

Initiated

Argus

Buy

$62

Apr-25-18

Downgrade

Wells Fargo

Outperform → Market Perform

Jan-24-18

Initiated

Goldman

Neutral

Jan-16-18

Reiterated

Chardan Capital Markets

Buy

$47 → $53

Jun-28-16

Reiterated

Singular Research

Buy

$44 → $40

Apr-15-16

Initiated

Chardan Capital Markets

Buy

$47

Mar-28-16

Initiated

Singular Research

Buy

$44

Feb-19-16

Initiated

Wells Fargo

Outperform

May-15-14

Initiated

Summer Street Research

Buy

$35

May-31-11

Reiterated

WBB Securities

Strong Buy

$20.50 → $30

Apr-19-21 10:45PM	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors Emergent BioSolutions Inc. - EBS PR Newswire -12.58%
06:19PM	Emergent Factory Halt Adds to Obstacles for J&Js Covid Vaccine Bloomberg
02:21PM	Emergent BioSolutions Investors With Losses Greater Than $100,000 Encouraged To Contact Kehoe Law Firm, P.C. GlobeNewswire
01:20PM	Emergent BioSolutions Stock Falls After FDA Initiates Inspection Of Bayview Facility Benzinga
12:39PM	Saxena White P.A. Files Securities Fraud Class Action Against Emergent BioSolutions Inc. GlobeNewswire
12:29PM	Why Emergent BioSolutions Stock Is Tumbling Today Motley Fool
06:42AM	UPDATE 4-J&J COVID-19 vaccine manufacturing halted at U.S. plant that had contamination issue Reuters
06:42AM	Emergent BioSolutions says it has agreed with FDA not to manufacture new material at Baltimore facility MarketWatch
05:45AM	Johnson & Johnson Slips on Vaccine Commitment As FDA Moves on EBS TheStreet.com
Apr-16-21 11:30PM	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors Emergent BioSolutions Inc. - EBS ACCESSWIRE
Apr-15-21 06:30AM	Emergent BioSolutions to Release First Quarter 2021 Financial Results and Conduct a Conference Call on April 29, 2021 GlobeNewswire
Apr-14-21 10:48PM	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors Emergent BioSolutions Inc. - EBS GlobeNewswire
Apr-13-21 03:35PM	Why Emergent BioSolutions Stock Fell Today Motley Fool
07:05AM	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors Emergent BioSolutions Inc. - EBS PR Newswire
Apr-12-21 09:00PM	EMERGENT BIOSOLUTIONS ALERT: Bragar Eagel & Squire, P.C. is Investigating Emergent BioSolutions, Inc. on Behalf of Emergent Stockholders and Encourages Investors to Contact the Firm Business Wire
Apr-10-21 08:01PM	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors Emergent BioSolutions Inc. - EBS Newsfile
Apr-09-21 11:51AM	Johnson & Johnson's COVID-19 Vaccine Under Review At EMA For Blood Clots, AstraZeneca Probe Expanded Benzinga
Apr-08-21 11:51AM	Entwistle & Cappucci LLP Investigative Alert: Emergent BioSolutions Inc. (EBS) Business Wire
10:45AM	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors Emergent BioSolutions Inc. - EBS ACCESSWIRE
09:41AM	Emergent BioSolutions Investor Alert: Kaplan Fox Investigates Potential Securities Fraud at Emergent BioSolutions GlobeNewswire
Apr-07-21 04:34PM	Biotech Stock Roundup: ACAD Down on CRL, EBS Gets Additional Order & Other Updates Zacks
03:13PM	Biotech Stock Roundup: ACAD Down on CRL, EBS Gets Additional Order & Other Updates Zacks
Apr-06-21 06:51PM	5 Peter Lynch Growth Stocks to Consider for 2nd Quarter GuruFocus.com
05:15AM	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors Emergent BioSolutions Inc. - EBS PR Newswire
04:14AM	Emergent BioSolutions Inc.'s (NYSE:EBS) Stock Has Been Sliding But Fundamentals Look Strong: Is The Market Wrong? Simply Wall St.
Apr-05-21 07:51PM	Johnson & Johnson Given Control of Emergent BioSolutions Factory That Botched Its Coronavirus Vaccine Motley Fool
01:33PM	UPDATE 1-White House says removal of AstraZeneca vaccine from U.S. plant will not affect dose output Reuters
11:28AM	White House's removal of AstraZeneca COVID-19 shot production from Emergent plant won't affect its dose output - official Reuters
11:00AM	Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Emergent BioSolutions Inc. (EBS) Investigation ACCESSWIRE
10:42AM	Emergent (EBS) Gets Extra $23M for COVID-19 Vaccine Production Zacks
10:13AM	U.S. COVID vaccine program speeds up to about 3 million doses a day in the past week MarketWatch
07:14AM	Emergent BioSolutions' Plasma-Based Therapy Candidate Flunks COVID-19 Study; HHS Increases Task Order By $23M Benzinga
07:05AM	J&J (JNJ) Gets Full Charge of Emergent COVID-19 Vaccine Plant Zacks
06:58AM	Emergent BioSolutions says on track with COVID vaccines, reaffirms guidance after J&J vaccine snafu MarketWatch
05:56AM	Another Look at Emergent Biosolutions TheStreet.com
04:47AM	Emergent Receives $23M From BARDA To Support Johnson & Johnson Vaccine Ramp Up SmarterAnalyst
Apr-04-21 10:54PM	Emergent gets $23 mln additional order for vaccine production Reuters
10:09PM	Emergent BioSolutions On Track with Respect to COVID-19 Contractual Commitments; Receives Modified Task Order from the U.S. Department of Health & Human Services to Support the Opportunity for Further Expansion of Manufacturing Capacity for Johnson & Johnsons COVID-19 Vaccine GlobeNewswire
01:32PM	US Puts Johnson & Johnson In Charge Of Troubled Vaccine Plant In Baltimore, Removes AstraZeneca Benzinga
Apr-02-21 09:51AM	Emergent says experimental COVID-19 treatment failed in Phase 3 trial MarketWatch
08:00AM	Emergent BioSolutions Announces Topline Data from NIAID Phase 3 ITAC Trial (INSIGHT-013) Evaluating Immunoglobulins as a Treatment for Hospitalized Patients with COVID-19 GlobeNewswire
Apr-01-21 06:56PM	Why Emergent BioSolutions Crashed Today Motley Fool -13.40%
10:35AM	Pfizer and BioNTech say their COVID-19 vaccine is safe and highly effective including against South Africa variant MarketWatch
08:36AM	Emergent's stock falls 6.8% after error making J&J's COVID-19 vaccine MarketWatch
08:12AM	Emergent BioSolutions Stock Falls After Vaccine Factory Mix-Up Barrons.com
05:51AM	15M Doses Of JNJ COVID-19 Vaccine Batch Ruined After Ingredient Issues At Emergent Biosolutions' US Plant: NYT Benzinga
05:26AM	Emergent, J&J Fall As Production Mix-Up To Cause Vaccine Delays Investing.com
Mar-31-21 08:00PM	J&J sticks to vaccine targets after batch ruined in factory error Financial Times
06:56PM	J&J Covid Vaccine Shipments Halted As Plant Mix-Up Ruins 15 Million Doses Investor's Business Daily
06:52PM	UPDATE 2-J&J finds problem with COVID vaccine batch; NYTimes says 15 mln doses ruined Reuters
Mar-25-21 01:24PM	Heres Why Emergent BioSolutions (EBS) Became One of Carillons Worst Securities Insider Monkey
Mar-23-21 02:32PM	UPDATE 3-J&J plant authorization clears way for big boost in U.S. COVID-19 shots Reuters
Mar-20-21 11:30AM	Why Is Emergent Biosolutions (EBS) Down 22.3% Since Last Earnings Report? Zacks
Mar-15-21 04:08PM	Top Pharmaceutical Stocks for Q2 2021 Investopedia
Mar-11-21 03:38PM	J&J to make up to 3 bln COVID-19 vaccines in 2022 -chief scientist Reuters
Mar-09-21 11:34AM	New York Times Credits Report On Emergent BioSolutions For Biden's Canceled Vaccine Plant Visit Benzinga
06:25AM	OPNT: NDA Filing on Track for 4Q21 Zacks Small Cap Research
Mar-08-21 10:55AM	White House Moves Event from Emergent Facility TheStreet.com -6.59%
Mar-04-21 11:57AM	Emergent Biosolutions CEO on JNJ vaccine production Yahoo Finance Video
06:08AM	Emergent BioSolutions Capable Of Manufacturing 1B COVID-19 Vaccine Doses Annually, CEO Says Benzinga
03:27AM	Emergent BioSolutions Turns Bearish, So Beware TheStreet.com
Mar-02-21 03:41AM	Morning Bell With Jim Cramer: Buy Emergent BioSolutions TheStreet.com
Mar-01-21 06:30AM	Emergent BioSolutions to Participate in Investor Conferences GlobeNewswire +6.46%
Feb-25-21 07:00AM	FOCUS-Wanted: More high-tech manufacturing space for a global vaccine push Reuters
Feb-24-21 10:07AM	Benzinga's Top Ratings Upgrades, Downgrades For February 24, 2021 Benzinga +5.68%
Feb-19-21 11:27AM	Why Emergent BioSolutions Stock Is Sliding Today Motley Fool -11.98%
10:57AM	Looking Into Emergent BioSolutions's Return On Capital Employed Benzinga
04:01AM	Emergent BioSolutions Inc (EBS) Q4 2020 Earnings Call Transcript Motley Fool
Feb-18-21 04:45PM	Emergent BioSolutions: Q4 Earnings Insights Benzinga
04:38PM	Dow Jones Closes Lower After Jobless Claims Report; GameStop House Hearing Begins Investor's Business Daily
04:25PM	UPDATE 3-Vaccine manufacturing deals power Emergent BioSolutions profit beat Reuters
04:05PM	Emergent BioSolutions Reports Financial Results for Fourth Quarter and Full Year 2020 GlobeNewswire
03:15PM	Emergent BioSolutions, Inc. to Host Earnings Call ACCESSWIRE
Feb-17-21 12:44PM	Co-Diagnostics Clears Technical Benchmark, Hitting 90-Plus RS Rating Investor's Business Daily
Feb-15-21 12:00AM	Shareholders Of Emergent BioSolutions (NYSE:EBS) Must Be Happy With Their 255% Total Return Simply Wall St.
Feb-11-21 06:14AM	3 Absurdly Cheap Coronavirus Stocks to Buy Now Motley Fool
Feb-10-21 01:40PM	Heat Biologics Stock Notches Scorching RS Rating Investor's Business Daily
Feb-04-21 02:37PM	IBD 50 Stocks To Watch: Emergent BioSolutions, A Biotech Stock With Solid Biodefense Cred Investor's Business Daily
01:54PM	Anavex Life Sciences Crp Earns 94 RS Rating; Soars To Record High Investor's Business Daily
06:30AM	Emergent BioSolutions to Release Fourth Quarter and Full Year 2020 Financial Results and Conduct a Conference Call on February 18, 2021 GlobeNewswire
Feb-03-21 12:08PM	Is Emergent Biosolutions (EBS) Stock a Buy For 2021? Insider Monkey
Feb-01-21 02:57PM	Horizon Pharma Sees Rising Composite Rating To 96 Investor's Business Daily +8.37%
01:45PM	Nasdaq Leads Market As Dow Jones Rises After Worst Week Since October; These Long-Term Leaders Near Buy Zones Investor's Business Daily
Jan-27-21 01:06PM	Stocks Showing Market Leadership: Sorrento Therapeutics Earns 93 RS Rating Investor's Business Daily
12:45PM	Emergent BioSolutions Getting Closer To Key Technical Benchmark Investor's Business Daily
Jan-26-21 03:39PM	Composite Rating For Pacira Pharmaceuticals Rises To 97 Investor's Business Daily
Jan-25-21 02:20PM	IBD Rating Upgrades: Supernus Pharmaceuticals Flashes Improved Price Strength Investor's Business Daily
01:21PM	Humanigen signs manufacturing deal with Emergent for experimental COVID-19 drug MarketWatch
08:30AM	Humanigen and Emergent BioSolutions Announce Contract Development and Manufacturing Agreement for Phase 3 COVID-19 Therapeutic Candidate Lenzilumab Business Wire
Jan-20-21 12:45PM	Top-Rated Stocks: Ligand Pharmaceuticals Sees Composite Rating Climb To 97 Investor's Business Daily
Jan-13-21 01:38PM	Emergent BioSolutions Sees Its Composite Rating Rise To 97 Investor's Business Daily
Jan-12-21 10:37AM	Emergent BioSolutions Is Looking Stronger TheStreet.com
Jan-11-21 09:22AM	Emergent (EBS) Posts Preliminary '20 Results, Gives 2021 View Zacks
09:15AM	How to Play Emergent BioSolutions Right Now TheStreet.com
Jan-10-21 02:00PM	Emergent BioSolutions Announces 2021 Financial Guidance, Provides Preliminary 2020 Results GlobeNewswire
Jan-07-21 12:45PM	3 Reasons Why Growth Investors Shouldn't Overlook Emergent Biosolutions (EBS) Zacks
Jan-06-21 05:50PM	Emergent Biosolutions (EBS) Outpaces Stock Market Gains: What You Should Know Zacks
11:30AM	Is Emergent Biosolutions (EBS) Outperforming Other Medical Stocks This Year? Zacks
Jan-05-21 07:03AM	Is Emergent BioSolutions Stock a Buy? Motley Fool
Jan-04-21 03:25PM	England Goes Under National Lockdown Barrons.com

Emergent BioSolutions Inc., a life sciences company, focuses on the provision of preparedness and response products and solutions for civilian and military populations that address accidental, deliberate, and naturally occurring public health threats (PHTs). The company's products address PHTs, which include chemical, biological, radiological, nuclear, and explosives; emerging infectious diseases; travel health; and emerging health crises and acute/emergency care. It offers ACAM2000, a smallpox vaccine; BioThrax, an anthrax vaccine; Vaxchora, a cholera vaccine; and Vivotif, a typhoid vaccine. The company also provides NARCAN for the emergency treatment of known or suspected opioid overdose; and Reactive Skin Decontamination Lotion Kit, a medical device to remove or neutralize chemical warfare agents from the skin. In addition, it offers raxibacumab for the treatment and prophylaxis of inhalational anthrax; Anthrasil to treat inhalational anthrax; Botulism Antitoxin Heptavalent for treating botulinum disease; vaccinia immune globulin intravenous that addresses complications from smallpox vaccination; and Trobigard a combination drug-device auto injector product candidate. Further, the company is developing COVID-EIG and COVID-HIG potential treatments to COVID-19 disease; and FLU-IGIV for the treatment of Influenza A infection in hospitalized patients. Additionally, it provides contract development and manufacturing service that comprises development services, drug substance manufacturing, and drug product manufacturing in the pharmaceutical and biotechnology industries, as well as the governments and non-governmental organizations. The company has collaboration agreements with Novavax Inc.; and Johnson & Johnson. Emergent BioSolutions Inc. was founded in 1998 and is headquartered in Gaithersburg, Maryland.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Bailey Sue	Director	Mar 04	Sale	92.37	8,168	754,478	24,427	Mar 08 06:30 PM
Havey Adam	EVP, Business Operations	Mar 01	Option Exercise	40.90	37,279	1,524,812	58,335	Mar 03 06:07 PM
Havey Adam	EVP, Business Operations	Mar 01	Sale	99.30	37,279	3,701,647	38,190	Mar 03 06:07 PM
Kramer Robert	President and CEO	Feb 08	Option Exercise	30.79	45,397	1,397,961	171,607	Feb 09 05:23 PM
Kramer Robert	President and CEO	Feb 08	Sale	120.03	45,397	5,449,002	139,210	Feb 09 05:23 PM
Kramer Robert	President and CEO	Jan 21	Option Exercise	26.45	21,900	579,255	161,110	Jan 22 04:14 PM
Kramer Robert	President and CEO	Jan 21	Sale	110.03	21,900	2,409,657	139,210	Jan 22 04:14 PM
Kramer Robert	President and CEO	Jan 20	Option Exercise	26.45	2,232	59,036	141,442	Jan 22 04:14 PM
Kramer Robert	President and CEO	Jan 20	Sale	110.00	2,232	245,520	139,210	Jan 22 04:14 PM
Kramer Robert	President and CEO	Jan 15	Option Exercise	25.62	19,026	487,446	158,236	Jan 19 04:28 PM
Kramer Robert	President and CEO	Jan 15	Sale	106.01	19,026	2,016,901	139,210	Jan 19 04:28 PM
El-Hibri Fuad	Chairman	Nov 10	Option Exercise	26.45	19,391	512,892	1,143,379	Nov 12 06:30 PM
El-Hibri Fuad	Chairman	Nov 10	Sale	88.21	19,391	1,710,480	1,123,988	Nov 12 06:30 PM
El-Hibri Fuad	Chairman	Nov 09	Option Exercise	26.45	20,000	529,000	1,143,988	Nov 12 06:30 PM
El-Hibri Fuad	Chairman	Nov 09	Sale	95.26	20,000	1,905,200	1,123,988	Nov 12 06:30 PM
El-Hibri Fuad	Chairman	Nov 03	Option Exercise	26.45	20,000	529,000	1,143,988	Nov 04 08:53 PM
El-Hibri Fuad	Chairman	Nov 03	Sale	90.74	20,000	1,814,800	1,123,988	Nov 04 08:53 PM
El-Hibri Fuad	Chairman	Nov 02	Option Exercise	26.45	20,000	529,000	1,143,988	Nov 04 08:53 PM
El-Hibri Fuad	Chairman	Nov 02	Sale	90.44	20,000	1,808,800	1,123,988	Nov 04 08:53 PM
El-Hibri Fuad	Chairman	Sep 24	Sale	98.85	12,535	1,239,085	1,123,988	Sep 25 07:00 PM
El-Hibri Fuad	Chairman	Sep 23	Sale	100.58	13,000	1,307,540	1,136,523	Sep 25 07:00 PM
El-Hibri Fuad	Chairman	Sep 17	Sale	100.68	20,000	2,013,600	1,149,523	Sep 18 06:25 PM
El-Hibri Fuad	Chairman	Sep 16	Sale	102.48	20,000	2,049,600	1,169,523	Sep 18 06:25 PM
El-Hibri Fuad	Chairman	Sep 10	Sale	102.66	20,000	2,053,200	1,189,523	Sep 11 09:21 PM
El-Hibri Fuad	Chairman	Sep 09	Sale	102.80	20,000	2,056,000	1,209,523	Sep 11 09:21 PM
SULLIVAN LOUIS W	Director	Sep 02	Option Exercise	20.08	7,893	158,491	50,655	Sep 04 08:08 PM
SULLIVAN LOUIS W	Director	Sep 02	Sale	111.22	28,418	3,160,606	42,762	Sep 04 08:08 PM
Bailey Sue	Director	Aug 18	Sale	128.31	4,665	598,564	32,595	Aug 19 05:08 PM
Harsanyi Zsolt	Director	Aug 17	Sale	133.71	6,609	883,664	24,579	Aug 18 09:12 AM
JOULWAN GEORGE A	Director	Aug 11	Sale	124.11	6,000	744,635	26,771	Aug 12 04:52 PM
Zoon Kathryn C	Director	Aug 10	Sale	130.27	1,000	130,270	12,489	Aug 11 04:43 PM
Richard Ronald	Director	Aug 07	Sale	131.00	6,297	824,907	8,276	Aug 11 04:46 PM
Richard Ronald	Director	Jun 03	Sale	87.51	6,572	575,142	4,269	Jun 05 04:36 PM
Bailey Sue	Director	Jun 03	Sale	87.50	5,322	465,691	37,260	Jun 05 04:33 PM
Hauer Jerome M	Director	May 26	Sale	85.15	4,385	373,373	10,188	May 27 05:10 PM
Zoon Kathryn C	Director	May 26	Sale	85.10	4,093	348,322	13,489	May 27 05:07 PM
Harsanyi Zsolt	Director	May 14	Option Exercise	18.64	3,434	64,010	28,367	May 18 07:12 PM
Zoon Kathryn C	Director	May 12	Sale	85.21	1,660	141,454	14,761	May 14 04:30 PM
Harsanyi Zsolt	Director	May 11	Sale	81.99	4,940	405,025	24,933	May 13 07:47 PM
JOULWAN GEORGE A	Director	May 11	Sale	85.19	2,000	170,371	29,950	May 13 07:45 PM
Richard Ronald	Director	May 05	Sale	80.19	8,375	671,629	8,020	May 06 05:08 PM
El-Hibri Fuad	Chairman	Apr 30	Sale	74.01	20,000	1,480,200	1,229,523	May 01 08:13 PM
El-Hibri Fuad	Chairman	Apr 29	Sale	74.24	20,000	1,484,800	1,249,523	May 01 08:13 PM
Richard Ronald	Director	Apr 27	Option Exercise	20.08	7,893	158,491	24,288	Apr 29 04:35 PM
Richard Ronald	Director	Apr 27	Sale	78.00	7,893	615,654	16,395	Apr 29 04:35 PM
El-Hibri Fuad	Chairman	Apr 23	Sale	68.49	20,000	1,369,800	1,269,523	Apr 24 04:16 PM
El-Hibri Fuad	Chairman	Apr 22	Sale	66.81	20,000	1,336,200	1,289,523	Apr 24 04:16 PM

open in yahoo | open in reuters | open in marketwatch | open in google

Upgrade your FINVIZ experience